Clinical Transfers®: Optimizing Frontline Immunotherapy for High PD-L1 Expressers with NSCLC

Program Overview

The landscape of precision medicine for non-small cell lung cancer (NSCLC) is continually evolving with an ever-expanding armamentarium of regimens targeting the PD-1/PD-L1 axis. In this activity, Roy S. Herbst, MD, PhD and Sarah B. Goldberg, MD, MPH, share the latest data for current and emerging checkpoint inhibitor monotherapies in advanced NSCLC with high PD-L1 expression and provide expert guidance on optimizing frontline treatment selection.

Credit Expired
0.50 CE Credit(s)
Expires: February 23, 2022

Target Audience

Oncologists and pulmonologists involved in the treatment of patients with non-small cell lung cancer (NSCLC).

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Analyze key safety and efficacy data for current and emerging frontline immunotherapy options in advanced non-small cell lung cancer (NSCLC) with programmed death-ligand 1 (PD-L1) expression levels ≥50%
  • Assess the potential impact of emerging frontline immunotherapeutic approaches on treatment selection in patients with advanced NSCLC and high PD-L1 expression

Activity Faculty

Herbst - Suit July 2013[2]

Roy S. Herbst, MD, PhD

Ensign Professor of Medicine (Medical Oncology) and Professor of Pharmacology
Chief of Medical Oncology

Associate Cancer Center Director, Translational Research
Yale Cancer Center and Smilow Cancer Hospital
New Haven, CT

Head Shot YMS2312_0228_Goldberg (2)

Sarah B. Goldberg, MD, MPH

Associate Professor of Medicine (Medical Oncology)
Yale Cancer Center and Smilow Cancer Hospital
New Haven, CT

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. 

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. 

© Copyright 2023. All rights reserved. Developed and managed by RMEI Medical Education, LLC. Laurel Office Plaza | 101 Laurel Road, Suite 200 | Voorhees, NJ 08043 | | (866) 770-RMEI


Stay up to date with the latest RMEI CE Activities and receive Exclusive Medical Education Resources